CHEO Research Institute Logo
Decrease Text SizeIncrease Text SizeFacebookTwitterYoutube

researchers working in a lab

Leanne Ward photo of Leanne Ward
Senior Scientist, CHEO Research Institute
Professor of Pediatrics
Research Chair in Pediatric Bone Health, University of Ottawa
Pediatric Endocrinologist
Medical Director, Pediatric Bone Health and Rare Bone Disease Program
Division of Endocrinology and Metabolism, CHEO

lward@cheo.on.ca
613-737-7600 Ext. 2253
Research Practice Areas:
Current Research:

Dr. Ward leads local, national and global research initiatives in the study of mechanisms, epidemiology and treatment of bone disorders in children, with an emphasis on osteoporosis in children with serious chronic illnesses. To date, musculoskeletal health has been studied in children with leukemia, rheumatic disorders, nephrotic syndrome, Duchenne muscular dystrophy, and inflammatory bowel disease. The main goal of the research program is to develop improved diagnostic and monitoring tools as well as treatment strategies for children with bone fragility due to osteoporosis. Dr. Ward’s areas of interest also extend to rickets (acquired and congenital) and skeletal dysplasias (such as osteogenesis imperfecta).

 
Research Team:
  • Suzanne Attallah
  • Stefan Jackowski
  • Nasrin Khan
  • Karine Khatchadourian
  • Victor Konji
  • Lynn MacLeay
  • Marika Page
  • Marie-Eve Robinson
  • Liz Sykes
Biography:

Dr. Leanne Ward is a Professor of Pediatrics at the University of Ottawa where she has held a Research Chair in Pediatric Bone Health since 2010. She is the Medical Director of the Pediatric Bone Health and Rare Bone Disease Clinical and Research Programs at the Children’s Hospital of Eastern Ontario, and a pediatric endocrinologist in the Division of Endocrinology and Metabolism. Dr. Ward’s research program is dedicated to the study of bone development and the diagnosis and treatment of bone disorders in children. She has been the principal investigator of the “STOPP” research program (STeroid-induced Osteoporosis in the Pediatric Population), a pan-Canadian project funded by the Canadian Institutes of Health Research to evaluate the effect of glucocorticoids on bone health in children with chronic illnesses. Dr. Ward actively leads and collaborates on a number of clinical trials for children with osteogenesis imperfecta, rickets and chronic illness osteoporosis. She has served as an endocrinology and bone health advisor to various international organizations on skeletal health in children, including the Centres for Disease Control Clinical Care Guidelines for Duchenne Muscular Dystrophy, the International Late Effects of Childhood Cancer Guideline Harmonization Group and the International Conference on Children’s Bone Health. Dr. Ward has received a number of awards for her work in pediatric bone health, including a Canadian Child Health Clinician Scientist Career Development Award, a Canadian Institutes for Health Research New Investigator Award, a Canadian Child Health Clinician Scientist Career Enhancement Award, and two, five-year Research Chairs in Pediatric Bone Health (University of Ottawa, 2010 and 2015).

Sample Publications:
Ward LM, Birnkrant DJ. Editor’s Comment: An Introduction to the Duchenne Muscular Dystrophy Care Considerations. Pediatrics, 142, (Supplement 2), S1-S4, 2018.

Ward LM, Hadjiyannakis S, McMillan HJ Noritz G and Weber DR. Bone Health and Osteoporosis Management of the Patient with Duchenne Muscular Dystrophy. Pediatrics, 142, (Supplement 2), S34-S42, 2018.

Weber, DR, Hadjiyannakis S, McMillan HJ Noritz G and Ward LM. Obesity and Endocrine Management of the Patient with Duchenne Muscular Dystrophy. Pediatrics, 142, (Supplement 2), S43-S52, 2018.

Piette AB, Hamoudi D, Marcadet L, Morin F, Argaw A, Ward LM, Frenette J. Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy. Current Osteoporosis Reports 16(5):541-553, 2018.

Ma J, Siminoski K, Alos N, Halton J, Ho J, Cummings EA, Shenouda N, Matzinger M, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis VA, Laverdière C, Israels S, Grant RM, Fernandez CV, Dix DB, Couch R, Cairney E, Barr R, Atkinson S, Abish S, Moher D, Rauch F, Ward LM, and the Canadian STOPP Consortium. Impact of vertebral fractures and glucocorticoid exposure on height deficits in children during treatment for leukemia. Journal of Clinical Endocrinology and Metabolism, 2018. Epub Sept 2018.

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavriodis P, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan M, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research, 136: 140–150, 2018.

Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger M, Shenouda N, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis V, Israels S, Grant RM, Fernandez CV, Dix DB, Cummings EA, Couch R, Cairney E, Barr R, Abish S, Atkinson SA, Hay J, Rauch F, Moher D, Siminoski K, Halton J and the Canadian STOPP Consortium. Bone Morbidity and Recovery in Children with Leukemia: Results of a Six-Year Prospective Longitudinal Study. Journal of Bone and Mineral Research, 33 (8) 1435–1443.

Ward LM, Rauch F. Anabolic Therapy for the Treatment of Osteoporosis in Childhood. Curr Osteoporos Rep. 16(3):269-276, 2018.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR for the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: updated recommendations on diagnosis, neuromuscular, rehabilitation, endocrine and nutritional management. Lancet Neurology, 17(3): 251-267, 2018.

Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, Case LE, Cripe L, Hadjiyannakis S, Olson AK, Sheehan D, Bolen J, Weber DR, Ward LM for the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, an update, part 2: Respiratory, cardiac, bone health, and orthopedic management. Lancet Neurology, 17(4):347-361, 2018.

Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, Cripe L, Herron AR, Kennedy A, Kinnett K, Naprawa J, Noritz G, Poysky J, Street N, Trout C, Webber DR, Ward LM, for the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 3: updated care considerations on primary care and emergency medicine, psychosocial care, and transitions of care across the lifespan. Lancet Neurology, 17(5):445-455, 2018.

Ward LM, Kinnett K, Bonewald L on Behalf of the Parent Project Muscular Dystrophy Bone Health Workshop Collaborators. Morbidity and Mortality due to Osteoporosis in Duchenne Muscular Dystrophy: The Path Forward. Neuromuscular Disorders, 28(1):64-76, 2018.

Trejo P, Rauch F, Ward L. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskeletal Neuronal Interact, 18(1):76-80, 2018. PMID: 29504582 
 
Ward LM, Konji VN, Ma J. Invited review. The Management of Osteoporosis in Children. Osteoporosis International, 27(7):2147–2179, 2016.
Take Action
Quick Links

Our Researchmagnifying glass

abcefg hijklmnopqrst uvwxyz